购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空
筛选
已筛选:全部清除
TargetMol | Tags 通过 Target 筛选
  • PDE
    (1)
  • Others
    (3)
筛选
搜索结果
TargetMol产品目录中 "

c33

"的结果
  • 抑制剂&激动剂
    5
    TargetMol | Inhibitors_Agonists
  • 重组蛋白
    2
    TargetMol | Recombinant_Protein
PDE9-IN-(S)-C33(S)-C33
T283522066488-39-7
PDE9-IN-(S)-C33 ((S)-C33) 是一种有效的选择性 PDE9 抑制剂 (IC50 = 11 nM)。 PDE9-IN-(S)-C33 可用于中枢神经系统疾病和糖尿病的相关研究。
  • ¥ 231
现货
规格
数量
TargetMol | Inhibitor Sale
EC330
T72932016795-77-8
EC330 是一种白血病抑制因子抑制剂。
  • ¥ 828
现货
规格
数量
TargetMol | Inhibitor Sale
EC33
T86337232261-88-0
EC33, a selective aminopeptidase A (APA) inhibitor, blocks the pressor response of exogenous Ang II and does not cross the blood-brain barrier, making it a potential candidate for salt-dependent hypertension research [1].
  • 询价
10-14周
规格
数量
NSC339614 potassiumNSC 339614 potassium,NSC-339614 potassium,NSC339614 potassium salt
T245511135037-53-4
NSC339614 potassium is a selective GluN1 GluN2C and GluN1 GluN2D receptors potentiator.
  • ¥ 10600
6-8周
规格
数量
IRC-083927 HCl
T68249955082-09-4
IRC-083927 HCl is novel and potent microtubule inhibitor with potential anticancer activity. IRC-083927 inhibits the tubulin polymerization by a binding to the colchicine site. IRC-083927 inhibits in vitro cell growth of human cancer cell lines in the low nanomolar range. More interesting, it remains highly active against cell lines resistant to microtubule-interacting agents (taxanes, Vinca alkaloids, or epothilones). Chronic oral treatment with IRC-083927 (5 mg/kg) inhibits the growth of two human tumor xenografts in nude mice (C33-A, human cervical cancer and MDA-MB-231, human hormone-independent breast cancer). Together, the antitumor effects induced by IRC-083927 on tumor models resistant to tubulin agents support further investigations to fully evaluate its potential for the treatment of advanced cancers, particularly those resistant to current clinically available drugs.
  • ¥ 10600
6-8周
规格
数量